Jean McClintock
Obstetrics & Gynecology · Dallas, TXNPI 1619979507
Payments from drug & device makers
Across 165 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$535
- Exeltis, USA Inc.$350
- Millicent US Inc$331
- Sumitomo Pharma America, Inc.$214
- Pfizer$178
- Therapeuticsmd, Inc.$127
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,94498%
- Education$672%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $535 |
| Exeltis, USA Inc. | 19 | $350 |
| Millicent US Inc | 16 | $331 |
| Sumitomo Pharma America, Inc. | 11 | $214 |
| Pfizer | 9 | $178 |
| Therapeuticsmd, Inc. | 8 | $127 |
| Sage Therapeutics, LLC | 7 | $124 |
| Aspira Women's Health Inc | 2 | $97 |
| Mayne Pharma Commercial LLC | 4 | $92 |
| Organon | 6 | $92 |
| Agile Therapeutics, Inc. | 4 | $80 |
| Hologic Sales And Service, LLC | 5 | $78 |
| Evofem Biosciences, Inc. | 3 | $61 |
| Mylan Pharmaceuticals Inc. | 4 | $53 |
| Astellas Pharma US Inc | 3 | $52 |
| Myovant Sciences Inc. | 3 | $50 |
| Avion Pharmaceuticals | 3 | $50 |
| Merck | 3 | $42 |
| Meditrina | 2 | $42 |
| Coopersurgical, Inc. | 2 | $36 |
| Lupin Inc. | 2 | $35 |
| Pacira Pharmaceuticals Incorporated | 2 | $32 |
| Exact Sciences | 2 | $31 |
| Vertical Pharmaceuticals, LLC | 2 | $29 |
| Innovation Technologies Inc | 1 | $25 |
| Medtronic | 1 | $23 |
| Integra Lifesciences Corporation | 1 | $21 |
| Shield Therapeutics Inc | 1 | $20 |
| Smith+Nephew | 1 | $18 |
| Mycovia Pharmaceuticals, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Duchesnay USA Incorporated | 1 | $14 |
How this compares
$3,010 in reported general payments places this provider in the 70th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 35 | $3,451 |
| YuvafemEstradiol | 12 | $1,310 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Dallas
- Clark GriffithDallas$1.3M
- Liesl BredesonDallas$964K
- Anna Lizama ClarkDallas$869K
- Dale StovallDallas$590K
- Stephanie SlocumDallas$470K
- Jeffrey NelsonDallas$354K
- A StaubDallas$328K
- Francesca PeruginiDallas$255K
- Quanita CrableDallas$176K
- Yolanda LawsonDallas$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.